Altogether, these data suggest that in breast cancer, ZNF217 mRNA expression is both a novel and powerful biomarker for poor prognosis and a prognostic predictor of patient outcome in response to chemotherapy. The gene discussed is ZNF217; the disease is breast carcinoma.